MCID: ORL005
MIFTS: 56

Oral Candidiasis

Categories: Gastrointestinal diseases, Infectious diseases, Oral diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Oral Candidiasis

MalaCards integrated aliases for Oral Candidiasis:

Name: Oral Candidiasis 12 54 15 17 71
Thrush 12 74 3
Candidiasis of Mouth 12
Candidiasis, Oral 43
Oral Moniliasis 12
Equine Thrush 71
Thrush, Oral 12
Candidiasis 71
Oral Thrush 62

Classifications:



External Ids:

Disease Ontology 12 DOID:14262
ICD9CM 34 112.0
MeSH 43 D002180
NCIt 49 C28137
SNOMED-CT 67 79740000
ICD10 32 B37.9
UMLS 71 C0006840 C0006849 C1299921

Summaries for Oral Candidiasis

PubMed Health : 62 About oral thrush: Oral thrush is a condition that can be difficult to recognize at first. It is rarely dangerous and not necessarily painful, but can be very unpleasant and greatly affect your quality of life. Oral thrush is caused by types of yeast fungus called Candida that live in the mucous membranes lining your mouth. Its medical name “oral candidiasis” is taken from this fungus. Oral thrush is most often caused by a type of Candida fungus called Candida albicans. Most people have small amounts of Candida on the mucous linings of their mouth without it causing any noticeable problems. But given the right conditions, the fungus can start reproducing very quickly. This often affects people who have serious diseases, and it can also be a side effect of certain types of treatment.

MalaCards based summary : Oral Candidiasis, also known as thrush, is related to denture stomatitis and stomatitis, and has symptoms including oral manifestations An important gene associated with Oral Candidiasis is SKAP2 (Src Kinase Associated Phosphoprotein 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Amphotericin B and Nystatin have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A candidiasis that involves fungal infection of the mucous membrane of the mouth by Candida species, which is characterized by thick white or cream-colored deposits on inflamed mucosal membranes.

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems.1 Sometimes, Candida can multiply and cause an infection if the environment inside the mouth, throat, or esophagus changes in a way that encourages fungal growth. Candidiasis in the mouth and throat is also called "thrush" or oropharyngeal candidiasis. Candidiasis in the esophagus (the tube that connects the throat to the stomach) is called esophageal candidiasis or Candida esophagitis. Esophageal candidiasis is one of the most common infections in people living with HIV/AIDS

Wikipedia : 74 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Related Diseases for Oral Candidiasis

Diseases related to Oral Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 307)
# Related Disease Score Top Affiliating Genes
1 denture stomatitis 31.3 SKAP2 DEFB4A CXCL8
2 stomatitis 31.2 IL1RN CXCL8 CD4
3 candida glabrata 30.9 SKAP2 HTN3
4 candidiasis 30.7 STAT1 SKAP2 SH2D1A HTN3 DEFB4A DEFB103B
5 vulvovaginal candidiasis 30.6 SKAP2 IL1RN DEFB4A DEFB1 CCR6
6 oral hairy leukoplakia 30.5 SH2D1A CD4
7 pustulosis of palm and sole 30.4 IL1RN CXCL8 CCR6
8 angular cheilitis 30.3 CD4 AIRE
9 chronic mucocutaneous candidiasis 30.2 STAT1 DEFB103B CD4 CCR6 AIRE
10 lymphadenitis 30.2 CXCL8 CD4 CCR6
11 vaginal discharge 30.2 SLPI CXCL8 CD4
12 esophageal candidiasis 30.2 CD4 CCR6 AIRE
13 bronchitis 30.2 STAT1 SLPI LTF CXCL8
14 histoplasmosis 30.1 STAT1 CD4 CCR6
15 pharyngitis 30.1 IL1RN CXCL8 CD4
16 pneumonia 30.1 SLPI IL1RN IL1A DEFB4A CXCL8
17 exanthem 30.1 IL1RN CXCL8 CD4 CCR6
18 osteomyelitis 30.1 STAT1 IL1RN IL1A CXCL8
19 blepharitis 30.0 STAT1 LTF CD4 CCR6
20 dermatophytosis 30.0 LTF DEFB4A CD4 CCR6
21 seborrheic dermatitis 29.9 IL1A DEFB4A CD4 CCR6
22 gingivitis 29.9 SLPI LTF IL1A DEFB4A CXCL8
23 immune deficiency disease 29.9 STAT1 SH2D1A IL1A CD4 CCR6 B2M
24 vaginitis 29.8 SLPI IL1A DEFB4A CXCL8 CD4 CCR6
25 salmonellosis 29.8 STAT1 DEFB4A DEFB1 CD4 CCR6
26 mastitis 29.8 SLPI LTF IL1RN CXCL8 CCR6
27 bacterial pneumonia 29.7 SLPI DEFB4A CXCL8 CD4 CCR6
28 behcet syndrome 29.7 IRF8 IL1RN IL1A CXCL8 CD4 CCR6
29 periodontitis 29.7 IL1RN IL1A DEFB4A DEFB103B DEFB1 CXCL8
30 psoriasis 29.7 SLPI IL1A DEFB4A CXCL8 CD4 CCR6
31 autoimmune disease 29.5 IL1RN IL1A CXCL8 CCR6 AIRE
32 myeloma, multiple 29.5 STAT1 IKBKB CXCL8 CD4 CCR6 B2M
33 fungal infectious disease 29.4 STAT1 SKAP2 CXCL8 CD4 CCR6 AIRE
34 leukemia, acute myeloid 29.4 STAT1 IRF8 CXCL8 CD4 CCR6 B2M
35 diabetes mellitus, type i 29.2 IL1RN CXCL8 CD4 CCR6 B2M AIRE
36 diabetes mellitus 29.1 SLPI IL1RN IL1A IKBKB CXCL8 CD4
37 skin disease 29.0 IL1A IKBKB DEFB4A DEFB103B CXCL8 CD4
38 bacterial infectious disease 28.9 LTF IL1RN IL1A DEFB4A DEFB103B DEFB1
39 systemic lupus erythematosus 28.8 STAT1 LTF IRF8 IL1RN IL1A CXCL8
40 median rhomboid glossitis 11.6
41 jak3-deficient severe combined immunodeficiency 11.3
42 immunodeficiency 32b 11.3
43 reticular dysgenesis 11.3
44 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 11.3
45 immunodeficiency 15a 11.3
46 leukoregulin 10.5 IL1A CXCL8
47 osteonecrosis of the jaw 10.5 DEFB4A DEFB103B DEFB1
48 corneal abscess 10.5 SLPI DEFB1
49 haemophilus influenzae 10.5 LTF CXCL8
50 geotrichosis 10.5 STAT1 CD4

Comorbidity relations with Oral Candidiasis via Phenotypic Disease Network (PDN): (show all 35)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alzheimer Disease Anxiety
Bronchitis Bronchopneumonia
Chronic Pulmonary Heart Disease Conn's Syndrome
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophageal Candidiasis
Esophagitis Familial Atrial Fibrillation
Glossitis Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Neutropenia
Osteoporosis Paralytic Ileus
Peripheral Vascular Disease Pharyngitis
Pneumocystosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Rheumatoid Arthritis Schizophreniform Disorder
Status Asthmaticus Swallowing Disorders
Vulvovaginal Candidiasis

Graphical network of the top 20 diseases related to Oral Candidiasis:



Diseases related to Oral Candidiasis

Symptoms & Phenotypes for Oral Candidiasis

UMLS symptoms related to Oral Candidiasis:


oral manifestations

GenomeRNAi Phenotypes related to Oral Candidiasis according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.72 DEFB4A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.72 CD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.72 CD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.72 DEFA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.72 DEFB4A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-160 9.72 CD4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-165 9.72 DEFB4A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.72 IKBKB
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.72 DEFA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.72 DEFA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.72 IKBKB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.72 CD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 IKBKB
14 Increased shRNA abundance (Z-score > 2) GR00366-A-200 9.72 DEFB4A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.72 DEFA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 CD4 DEFA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.72 IKBKB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.72 IKBKB
19 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.72 DEFA1 DEFB4A IKBKB
20 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.72 IKBKB
21 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.72 DEFA1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 IKBKB

MGI Mouse Phenotypes related to Oral Candidiasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 AIRE B2M CCR6 CD4 IKBKB IL1A
2 immune system MP:0005387 9.44 AIRE B2M CCR6 CD4 IKBKB IL1A

Drugs & Therapeutics for Oral Candidiasis

PubMed Health treatment related to Oral Candidiasis: 62

Oral thrush can be treated with antimycotics. These are available as drugs that produce either a topical (local) or a systemic (throughout the whole body) effect. Medication that acts in both ways is also an option. The type of medication that is best suited for someone with a weakened immune system will depend on their individual situation.

Drugs for Oral Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
2
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
3
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
4
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
5
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
6
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
7
Voriconazole Approved Phase 4 137234-62-9 71616
8
Dequalinium Approved, Investigational Phase 4 6707-58-0
9
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
10
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
11
Racepinephrine Approved Phase 4 329-65-7 838
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
14
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
15
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
16
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
17
Nevirapine Approved Phase 4 129618-40-2 4463
18
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
19
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
20
Zidovudine Approved Phase 4 30516-87-1 35370
21
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
22
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
23
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
24
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
25
Salmeterol xinafoate Phase 4 94749-08-3 56801
26 Adrenergic beta-Agonists Phase 4
27 Adrenergic Agents Phase 4
28 Fluticasone-Salmeterol Drug Combination Phase 4
29 Adrenergic Agonists Phase 4
30 Sympathomimetics Phase 4
31 Gentamicins Phase 4
32 Pharmaceutical Solutions Phase 4
33 Immunologic Factors Phase 4
34 Liposomal amphotericin B Phase 4
35 Ionophores Phase 4
36 Anti-Infective Agents, Local Phase 4
37 Dermatologic Agents Phase 4
38 Disinfectants Phase 4
39 Cytochrome P-450 CYP3A Inhibitors Phase 4
40 Respiratory System Agents Phase 4
41 Anti-Asthmatic Agents Phase 4
42 glucocorticoids Phase 4
43 Anti-Inflammatory Agents Phase 4
44 Eusol Phase 4
45 Sodium hypochlorite Phase 4
46 Hydrocortisone 17-butyrate 21-propionate Phase 4
47 Hydrocortisone hemisuccinate Phase 4
48 Clindamycin phosphate Phase 4
49 Clindamycin palmitate Phase 4
50 Epinephryl borate Phase 4

Interventional clinical trials:

(show top 50) (show all 345)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
2 Diagnosis of Pulmonary Candidiasis Unknown status NCT00537888 Phase 4 fluconazole
3 A Randomized Clinical Trial Between Clindamycin Once and Thrice a Day in Septic Abortion. Unknown status NCT02309346 Phase 4 Clindamycin
4 A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis Completed NCT00000951 Phase 4 Fluconazole
5 Oral Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
6 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
7 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
8 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
9 Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE Completed NCT00194324 Phase 4 Miconazole nitrate
10 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
11 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
12 Effectiveness and Safety of Daktacort Feminine Care Cream in the Treatment of Vulvar Candidiasis Completed NCT01769339 Phase 4 Miconazole plus Hydrocortisone
13 Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis Completed NCT01994096 Phase 4 Caspofungin
14 A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting Completed NCT00520234 Phase 4 Caspofungin;Normal Saline
15 Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
16 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
17 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients Completed NCT01734525 Phase 4 Anidulafungin
18 Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
19 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
20 CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis in Non-Neutropenic Patients Completed NCT00670657 Phase 4 AmBisome
21 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
22 Clinical Evaluation of an Experimental Solution Based on Ricinus Communis Compared to Sodium Hypochlorite for Denture Cleansing Completed NCT02407834 Phase 4
23 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Completed NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
24 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
25 Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk Completed NCT00001107 Phase 4 Fluconazole;AmBisome
26 The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients Completed NCT01495039 Phase 4 Nystatin
27 Micafungin (Mycamine®) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (MICADO). Completed NCT03102658 Phase 4 Micafungin
28 The Clinical Effect in Asthma of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols Completed NCT01662778 Phase 4 1.5 microns at 50mg;6 microns at 50mg;Placebo Comparator;MDI FP
29 Pharmacokinetics of Anidulafungin (Ecalta ®) Given Intravenously as Prophylaxis to Obese Patients With Risk of Invasive Fungal Infection Undergoing Gastric Bypass Surgery. Completed NCT02021123 Phase 4 Anidulafungin 100mg single dose iv
30 A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
31 Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers Completed NCT01307930 Phase 4 Anidulafungin
32 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
33 A Comparative Clinical and Immunohistochemical Study Between Topical Pimecrolimus and Corticosteroid in Treatment of Oral Lichen Planus Completed NCT02443311 Phase 4 Pimecrolimus 1% cream;Betamethasone 17-valerate 0.1% cream
34 Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy Completed NCT01539330 Phase 4 Voriconazole
35 Multicenter Study to Compare Two Diagnostic Tests (1,3-β-D-glucan vs Blood Culture) in Critically Ill Patients With Suspected Invasive CAndidiasis Hospitalized in Internal Medicine Wards and Who Are Currently Timely Treated With Echinocandin (Micafungin) Recruiting NCT03906916 Phase 4 Micafungin
36 Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA) Recruiting NCT04122560 Phase 4 Fluconazole 200mg tab;Fluconazole 2 MG/ML
37 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
38 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Active, not recruiting NCT03723525 Phase 4
39 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment) Terminated NCT01982071 Phase 4 Micafungin
40 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
41 Study for the Assessment of Safety and Efficacy of Ciclopirox Olamine Cream in 3 Months to 10 Years Old Children With Dermatomycoses Terminated NCT01646580 Phase 4 ciclopirox
42 Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095 Terminated NCT00177749 Phase 4 Posaconazole
43 A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic Patients Withdrawn NCT00304772 Phase 4 Fluconazole;Micafungin
44 "A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis ". Unknown status NCT02635438 Phase 3 Unique Pharmaceutical Laboratories, India;Roxane Laboratories Inc., USA
45 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
46 Fluconazole Versus Micafungin in Neonates With Suspected or Culture-proven Candidiasis: a Randomized Pharmacokinetic and Safety Study (TINN Project - Treat Infections iN Neonates) Unknown status NCT02145832 Phase 2, Phase 3 Fluconazole;Micafungin
47 Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis Unknown status NCT03473418 Phase 3 Ketoconazole;Terconazole
48 Dysbiosis in the Vaginal Microbiota May be Associated With the Development of Localized Provoked Vulvodynia (LPV) Unknown status NCT02393911 Phase 3
49 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People Completed NCT02818803 Phase 3 Miconazole
50 Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients Completed NCT00002446 Phase 3 Posaconazole;Fluconazole

Search NIH Clinical Center for Oral Candidiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorhexidine
chlorhexidine gluconate
Clotrimazole
Fluconazole
Flucytosine
Itraconazole
Ketoconazole
NYSTATIN PWDR

Cochrane evidence based reviews: candidiasis, oral

Genetic Tests for Oral Candidiasis

Anatomical Context for Oral Candidiasis

MalaCards organs/tissues related to Oral Candidiasis:

40
Colon, Testes, Skin, Tongue, Liver, Myeloid, Kidney

Publications for Oral Candidiasis

Articles related to Oral Candidiasis:

(show top 50) (show all 3117)
# Title Authors PMID Year
1
Differential expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes. 54 61
15472333 2004
2
[Development of murine experimental model for candidiasis and its application]. 54 61
15550920 2004
3
Susceptibility of Candida dubliniensis to salivary histatin 3. 61 54
12499171 2003
4
Nonspecific secretory immunity in HIV-infected patients with oral candidiasis. 61 54
12439202 2002
5
Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. 54 61
11936455 2002
6
Increased serum and salivary immunoglobulins against Candida albicans in HIV-infected patients with oral candidiasis. 54 61
11506465 2001
7
Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways. 61 54
11083633 2000
8
Complete response of severe, refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme. 61 54
11089630 2000
9
In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. 54 61
10225911 1999
10
Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ cell count falls below 200/microL. SEROCO & HEMOCO Study Group. 54 61
9839750 1998
11
Age, gender, and other predictors of the wasting syndrome among HIV-1-infected injecting drug users. 61 54
7742405 1995
12
Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. 61 54
7932082 1994
13
Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. 54 61
1569421 1992
14
Fluorescence staining vs. routine KOH smear for rapid diagnosis of oral candidiasis-A diagnostic test. 61
32011074 2020
15
Anaplasmataceae closely related to Ehrlichia chaffeensis and Neorickettsia helminthoeca from birds in Central Europe, Hungary. 61
32318980 2020
16
Pyostomatitis vegetans in a pediatric patient with ulcerative colitis: case report of a rare pediatric inflammatory bowel disease extraintestinal manifestation and review of the literature. 61
32282544 2020
17
[Pathogenicity and drug-resistance analysis of Candida glabrata in patients with oral candidiasis]. 61
32536122 2020
18
Suppressive effects of 2-methacryloyloxyethyl phosphorylcholine (MPC)-polymer on the adherence of Candida species and MRSA to acrylic denture resin. 61
32577575 2020
19
In vitro and in vivo evaluation of the antifungal activity of fluoxetine combined with antifungals against Candida albicans biofilms and oral candidiasis. 61
32551919 2020
20
Study of the activity of Punica granatum-mediated silver nanoparticles against Candida albicans and Candida glabrata, alone or in combination with azoles or polyenes. 61
31509195 2020
21
Oral epithelial IL-22/STAT3 signaling licenses IL-17-mediated immunity to oral mucosal candidiasis. 61
32503875 2020
22
Meat quality and lipid fatty acid profile from wild thrush (Turdus philomelos), woodcock (Scolopax rusticola) and starling (Sturnus vulgaris): a preliminary comparative study. 61
32487110 2020
23
Vultures from different trophic guilds show distinct oral pathogenic yeast signatures and co-occurrence networks. 61
32224410 2020
24
Correlates of bird collisions with buildings across three North American countries. 61
32537779 2020
25
Guanidine derivative inhibits C. albicans biofilm growth on denture liner without promote loss of materials' resistance. 61
32123776 2020
26
Periodontitis and cytomegalovirus associate with atherosclerosis among HIV patients after 5 years on ART. 61
32541382 2020
27
Molecular Identification of Candida Species in the Oral Microbiota of Individuals with Down Syndrome: A Case-Control Study. 61
32458314 2020
28
Probiotics as a prophylaxis to prevent oral candidiasis in patients with Sjogren's syndrome: a double-blinded, placebo-controlled, randomized trial. 61
32219478 2020
29
Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study. 61
32275086 2020
30
Spacers and Valved Holding Chambers-The Risk of Switching to Different Chambers. 61
31927099 2020
31
Temperature-dependent mucosal permeation kinetics of stigmasterol microspheres: In vivo mice model antioral candidiasis study. 61
31721433 2020
32
Activity of bioactive garlic compounds on the oral microbiome: a literature review. 61
32348240 2020
33
Development of Probiotic Formulations for Oral Candidiasis Prevention: Gellan Gum as a Carrier To Deliver Lactobacillus paracasei 28.4. 61
32253208 2020
34
A mixed-method simulated patient approach to explore implicit bias in health care: A feasibility study in community pharmacy. 61
32417071 2020
35
Antifungal Activity of Capric Acid, Nystatin, and Fluconazole and Their In Vitro Interactions Against Candida Isolates from Neonatal Oral Thrush. 61
32392426 2020
36
Analysis of Phytochemical Composition of Camellia oleifera Oil and Evaluation of its Anti-Inflammatory Effect in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages. 61
32394442 2020
37
Methylene blue mediated antimicrobial photodynamic therapy in clinical human studies: The state of the art. 61
32473398 2020
38
Evaluation of nanomaterials to prevent oral Candidiasis in PMMA based denture wearing patients. A systematic analysis. 61
32373449 2020
39
The Interactions between the Antimicrobial Peptide P-113 and Living Candida albicans Cells Shed Light on Mechanisms of Antifungal Activity and Resistance. 61
32290246 2020
40
Alginate-poloxamer beads for clotrimazole delivery: Molecular interactions, mechanical properties, and anticandidal activity. 61
31982519 2020
41
A New Isosporan (Apicomplexa: Eimeriidae) from Wood Thrush, Hylocichla mustelina (Aves: Passeriformes: Turdidae), in Oklahoma. 61
32296848 2020
42
Morphological and molecular identification of Isospora massardi Lopes, Berto, Luz, Galvão, Ferreira & Lopes, 2014 (Chromista: Miozoa: Eimeriidae) from thrushes Turdus spp. (Passeriformes: Turdidae) in South America. 61
31843685 2020
43
Modeling avian full annual cycle distribution and population trends with citizen science data. 61
31837058 2020
44
First serological evidence of West Nile virus infection in wild birds in Northern Algeria. 61
31945717 2020
45
Immune Dysregulation after Pediatric Heart Transplantation. 61
32465787 2020
46
Individualized prediction of late-onset dysphagia in head and neck cancer survivors. 61
32031294 2020
47
The role of autophagy in the pathogenesis of periodontal disease. 61
30674085 2020
48
Effects of CD4 cell count and antiretroviral therapy on mucocutaneous manifestations among HIV/AIDS patients in Yunnan, China. 61
31846069 2020
49
Efficacy of antifungal drugs in the treatment of oral candidiasis: A Bayesian network meta-analysis. 61
32165010 2020
50
Mercury exposure in songbird communities along an elevational gradient on Whiteface Mountain, Adirondack Park (New York, USA). 61
32232628 2020

Variations for Oral Candidiasis

Expression for Oral Candidiasis

Search GEO for disease gene expression data for Oral Candidiasis.

Pathways for Oral Candidiasis

Pathways related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 STAT1 SLPI SH2D1A LTF IRF8 IL1RN
2
Show member pathways
13.12 STAT1 IRF8 IL1RN IL1A IKBKB CXCL8
3
Show member pathways
12.71 STAT1 IKBKB CXCL8 CD4 CCR6
4
Show member pathways
12.68 STAT1 IL1A CXCL8 CD4 B2M
5
Show member pathways
12.63 STAT1 IL1A IKBKB CXCL8 B2M
6
Show member pathways
12.51 STAT1 IL1RN IL1A IKBKB CXCL8
7 12.25 STAT1 SH2D1A IRF8 IL1RN IKBKB B2M
8
Show member pathways
12.15 STAT1 IL1A IKBKB CXCL8
9
Show member pathways
11.95 STAT1 IKBKB DEFB4A CXCL8
10 11.89 STAT1 IKBKB DEFB4A DEFB103B DEFA1 CXCL8
11 11.74 STAT1 IL1A CXCL8
12
Show member pathways
11.72 STAT1 IKBKB CD4 B2M
13 11.6 DEFB4A DEFB103B DEFB1 DEFA1
14 11.57 IRF8 IL1A CXCL8
15
Show member pathways
11.56 LTF HTN3 DEFB4A DEFB103B DEFB1 DEFA1
16
Show member pathways
11.47 IL1A IKBKB CXCL8
17 11.32 IL1RN IL1A CXCL8

GO Terms for Oral Candidiasis

Cellular components related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 SLPI LTF IL1RN IL1A HTN3 DEFB4A
2 Golgi lumen GO:0005796 9.46 DEFB4A DEFB103B DEFB1 DEFA1
3 specific granule lumen GO:0035580 9.43 SLPI LTF B2M
4 extracellular space GO:0005615 9.32 SLPI LTF IL1RN IL1A DEFB4A DEFB103B

Biological processes related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.04 SLPI SH2D1A LTF IRF8 CD4 B2M
2 cytokine-mediated signaling pathway GO:0019221 9.92 STAT1 IL1RN IL1A CXCL8 CD4
3 chemotaxis GO:0006935 9.91 DEFB4A DEFB103B DEFB1 DEFA1 CXCL8 CCR6
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.86 LTF IL1A IKBKB CD4
5 cellular response to lipopolysaccharide GO:0071222 9.85 IRF8 IL1A DEFA1 CXCL8
6 defense response GO:0006952 9.85 STAT1 DEFB4A DEFB103B DEFB1 DEFA1 CXCL8
7 defense response to Gram-positive bacterium GO:0050830 9.81 DEFB4A DEFB103B DEFB1 DEFA1
8 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.8 LTF DEFB4A DEFB1 DEFA1 CXCL8
9 interleukin-1-mediated signaling pathway GO:0070498 9.79 IL1RN IL1A IKBKB
10 cell chemotaxis GO:0060326 9.78 DEFB4A DEFB103B CCR6
11 humoral immune response GO:0006959 9.78 SH2D1A LTF CCR6 AIRE
12 interferon-gamma-mediated signaling pathway GO:0060333 9.76 STAT1 IRF8 B2M
13 antibacterial humoral response GO:0019731 9.76 SLPI LTF DEFB1 DEFA1
14 defense response to bacterium GO:0042742 9.76 SLPI LTF IRF8 HTN3 DEFB4A DEFB103B
15 defense response to Gram-negative bacterium GO:0050829 9.73 LTF DEFB4A DEFB103B DEFB1 DEFA1 CD4
16 killing of cells of other organism GO:0031640 9.72 LTF HTN3 DEFB4A DEFB103B DEFA1
17 innate immune response in mucosa GO:0002227 9.67 LTF DEFB1 DEFA1
18 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.61 IL1A CD4
19 response to molecule of bacterial origin GO:0002237 9.6 CXCL8 B2M
20 killing by host of symbiont cells GO:0051873 9.59 DEFB103B DEFA1
21 membrane disruption in other organism GO:0051673 9.58 LTF DEFA1
22 positive regulation of flagellated sperm motility involved in capacitation GO:0060474 9.54 DEFB1 CCR6
23 antimicrobial humoral response GO:0019730 9.43 LTF HTN3 DEFB4A DEFB103B DEFB1 DEFA1
24 immune response GO:0006955 9.4 SLPI IRF8 IL1RN IL1A DEFB4A DEFB1

Molecular functions related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 8.96 IL1RN IL1A
2 CCR6 chemokine receptor binding GO:0031731 8.8 DEFB4A DEFB103B DEFB1

Sources for Oral Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....